Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity

Therapeutic Drug Monitoring

Volumn 24, Issue 6, 2002, Pages 715-721

  Sinués, Blanca ^a   Fanlo, Ana ^a   Luisa Bernal, María ^a   Mayayo, Esteban ^a   Antonia Soriano, María ^a   Martínez Ballarin, Enrique ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Caffeine metabolite ratios; CYP1A2 activity; Urine flow

Indexed keywords

CAFFEINE; CAFFEINE DERIVATIVE; CYTOCHROME P450 1A2; OMEPRAZOLE; CENTRAL STIMULANT AGENT;

ADULT; ARTICLE; CALCULATION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLITE; NORMAL HUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION; URINE FLOW RATE; ADOLESCENT; BIOSYNTHESIS; BIOTRANSFORMATION; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; URODYNAMICS;

ADOLESCENT; ADULT; BIOTRANSFORMATION; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; URODYNAMICS;

EID: 0036890584     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200212000-00006     Document Type: Article

References (42)

1. Lemoine A, Gautier JC, Azoulay D. Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P4503A4 in human liver. Mol Pharmac 1993;43:827-32.
2. Nielsen KK, Brösen K, Hansen J, et al. Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
3. Bertilsson L, Carrillo JA, Dahl ML. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
4. Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60: 183-90.
5. Ring BJ, Catlow J, Lindsay TJ. Identification of the human cytochromes P450 responsible for the in vitro formation of major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
6. Madden S, Woolf TF, Pool WF, et al. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993;46:13-20.
7. Arlander E, Ekstrom G, Alm C. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998;64:484-91.
8. Shimada T, Iwasaki M, Martin MV, et al. Human liver microsomal cytochrome P450 enzymes involved in the bioactivation of procarcinogens detected by mu gene response in Salmonella typhi murium TA1535/psk 1002. Cancer Res 1989;49:3218-28.
9. Kitada M, Taneda M, Ohta K, et al. Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazol (4-5-f)-quinoline by human adult and fetal liver. Cancer Res 1990;50:2641-5.
10. Gallagher EP, Wienkers LC, Stapleton PL, et al. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res 1994;54:101-8.
11. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
12. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 1991;4:391-407.
13. Brosen K, Skelbo E, Rasmuseen B, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45: 1211-4.
14. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in the metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348:332-7.
15. Fuhr U, Anders EM, Mahr G, et al. Inhibitory potency of quinolone antibacterial agents on cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942-8.
16. Botsch S, Gautier JC, Beaune P, et al. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993;43:120-6.
17. Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994;47: 1767-76.
18. Gu L, Gonzalez FJ, Kalow W, et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2EI. Pharmacogenetics 1992;2:73-7.
19. Kalow W, Tang BK. The use of caffeine for enzyme assays: A critical appraisal. Clin Phamacol Ther 1993;53:503-14.
20. Tang BK, Grant DM, Kalow W. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab Dispos 1983;11:218-20.
21. Kadlubar FF, Talaska G, Butler MA, et al. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. In: Mendelsohn ML, Albertini RJ, eds. Mutation and the Environment. Part B: Metabolism, Testing Methods and Chromosomes. New York: John Wiley, 1990:107-14.
22. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human population by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
23. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
24. Carrillo JA, Benítez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304.
25. Tang BK, Zhou Y, Kadar D, et al. Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994;4:117-24.
26. Sinués B, Sáienz MA, Lanuza J, et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomark Prev 1999;8:159-66.
27. Andersson T, Holmberg J, Röhss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1988;45:369-75.
28. Rizzo N, Padoin C, Palombo S, et al. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996;49:491-5.
29. Rost KL, Roots Y. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-11.
30. Kadlubar FF, Butler MA, Kaderlik RK, et al. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis. Environ Health Perspect 1992;98:69-74.
31. Conney AH, Panzuck KJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal broiled beef. Clin Pharmacol Ther 1976;20:633-42.
32. Vistisen K, Loft S, Poulsen HE. Cytochrome P4501A2 activity in man measured by caffeine metabolism: Effect of smoking, broccoli and exercise. Adv Exp Med Biol 1990;283:407-11.
33. Grant DM, Tang BK, Kallow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983;33:355-9.
34. Tang BK, Kadar D, Quian L, et al. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991;49:648-57.
35. Birkett DJ, Miners JO. Caffeine renal clearance and urine caffeine concentration during steady state dosing. Implications for monitoring caffeine intake during sports events. Br J Clin Pharmacol 1991;31:405-8.
36. Bonati M, Latini R, Galleti F, et al. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982;32:98-106.
37. Tang-Liu DDS, Tozer TN, Riegelman S. Dependence of renal clearance on urine flow: A mathematical model and its application. J Pharm Sci 1983;72:154-8.
38. Blanchard J, Sawers SJA. Relationship between urine flow rate and clearance of caffeine in man. J Clin Pharmacol 1983;23:134-8.
39. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
40. Notarianni LJ, Oliver SE, Dobrocky P, et al. Caffeine as a metabolic probe: A comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995;39:65-9.
41. Aramaki S, Ishidaka O, Suzuki E, et al. Theoretical relationship between the post-administration time and plasma or urinary concentration of a metabolite and the unchanged drug. Administration of caffeine to horses. Biol Pharm Bull 1996;19:1341-6.
42. Nakajima M, Yokoi T, Mizutani M, et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994;3:413-21.